An interventional study of aerobic exercise training in Heart Failure and Type 2 Diabetes, sponsored by Duke University. Withdrawn at 1 site in United States. Open to participants aged 50 Years to 99 Years. Per ClinicalTrials.gov, last updated 2023-06-15.
Sponsored by Duke University · Not applicable, Interventional, and Treatment
The purpose of this study is to understand the differences in how patients with heart failure respond to exercise training compared to patients with heart failure and type 2 diabetes.
The investigators will measure exercise capacity in patients with heart failure or heart failure plus type 2 diabetes prior to and following a 12-week exercise training program (5d/wk, 30 min/d, 60-75% VO2max) to determine whether improvements in exercise capacity in response to exercise training are mitigated in patients with combined heart failure plus type 2 diabetes.
5,701 studies on the registry are indexed under Heart Failure; 1,220 are open to participants now.
Browse Heart Failure studies →Duke University is the lead sponsor of 2,025 studies on the registry; 275 are open to participants now.
Of its 194 completed or terminated interventional studies of FDA-regulated products, 159 (82%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
aerobic exercise training
Behavioral: aerobic exercise training
aerobic exercise training
Behavioral: aerobic exercise training
12 weeks of supervised aerobic exercise training
exercise capacity
measured as peak oxygen consumption as well as treadmill time to exhaustion, also known as cardiopulmonary fitness
Time frame: baseline, 12 weeks
flow-mediated dilation
brachial artery flow-mediated dilation
Time frame: baseline, 12 weeks
nitrite flux during exercise
changes in plasma nitrite during exercise
Time frame: baseline, 12 weeks
This study is withdrawn, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Duke University